National Institute of Mental Health (NIMH)
Trial Pipeline
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
NCT07169630
Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B)
NCT07027839
PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)
NCT06920628
Assessment of 11C-JMJ-129 for Imaging PDE4D in Brain and Whole Body of Healthy Volunteers
NCT06874205
PET Imaging of Phosphodiesterase-4B (PDE4B) in Alcohol Use Disorder
NCT06795581
Study Brain Mechanisms of Frustration With Magnetoencephalography in Healthy Volunteers
NCT06484088
Gaze-Contingent Music Therapy Augmentation of CBT for Pediatric Anxiety
NCT06595953
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
NCT06511908
Natural History of Depression, Bipolar Disorder and Suicide Risk
NCT06462196
Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial
NCT05608434
NIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, and Bipolar Disorder
NCT05669703
State-dependent Interoception, Value-based Decision-making, and Introspection
NCT05666726
[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET
NCT05703685
Developing Brain, Impulsivity and Compulsivity
NCT04631042
Characterization of an Optically Pumped Magnetometer (OPM) Magnetoencephalography (MEG) Array
NCT04950309
Electrophysiologic Sleep Phenotyping and Sleep-Dependent Neuro-maturation in Clinical and Healthy Pediatric Populations
NCT04639830
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
NCT04396873
Long-term Observation of Participants With Mood Disorders
NCT04877977
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
NCT04582916
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
NCT04798274
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
NCT03973268
Characterization and Treatment of Adolescent Depression
NCT03388606
Recruitment and Characterization of Healthy Research Volunteers for NIMH Intramural Studies
NCT03304665
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
NCT03065335
Neurobiology of Suicide
NCT02543983
Psychological Treatments for Youth With Severe Irritability.
NCT02531893
Brain Stimulation and Vision Testing
NCT01617408
Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01778504
Top-Down Attentional Control of Visual-Processing
NCT01087281
A Longitudinal Investigation of the Endocrine and Neurobiologic Events Accompanying Puberty
NCT01434368
Development of Magnetic Resonance Spectroscopic Imaging Techniques for Imaging Metabolites in Human Brain and Muscle
NCT01266577
Defining the Brain Phenotype of Children With Williams Syndrome
NCT01132885
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
NCT00397111
MRS Measurement of Glutamate and GABA Metabolism in Brain
NCT00109174
The Neurodevelopmental and Behavioral Phenotyping Screening Protocol
NCT00271622
Studies of Brain Function and Course of Illness in Pediatric Bipolar Disorder
NCT00025935
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
NCT00018057
Evaluation of Patients With Mood and Anxiety Disorders and Healthy Volunteers
NCT00024635
Studies of Blood Flow to the Brain During Thought
NCT00001360
Study of Premenstrual Syndrome and Premenstrual Dysphoria
NCT00001177
Transcranial Electric Stimulation Therapy (TEST) for Treatment Resistant Depression (TRD)
NCT05172271
Evaluation of the Genetics of Bipolar Disorder
NCT00001174
Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers
NCT00001246
Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers
NCT04339790
PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of McCune-Albright Syndrome
NCT02743377
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder
NCT02484456
Cognitive vs. Emotional Psychopharmacological Manipulations of Fear vs. Anxiety
NCT02153944
Evaluation of Two Radioactive Chemicals to Image mGluR5 Receptors in Brain
NCT01896843
Study of [11C]DPA-713 for Temporal Lobe Epilepsy
NCT01793532
(18F)FCWAY and the Blood-Brain Barrier
NCT01386476
Study of Toddlers With Language Delay
NCT01339767
Brain Imaging Study of Adults With Autism Spectrum Disorders
NCT01093768
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
NCT00942981
Characterizing Lone Parenting: A Multi-institutional Pilot Study of the Perceptions of Support and Perceived Stress of Lone Parents of Children With Cancer
NCT00969579
Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's Disease
NCT00955422
Development and Decline of Brain and Cognition Through the Life Span
NCT00880451
Imaging Cannabinoid CB1 Receptors in Alcohol Dependence
NCT00816439
Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia
NCT00802100
p11 Protein Levels in Patients With Major Depressive Disorder Treated With Citalopram
NCT00697268
Combining Medications to Enhance Depression Outcomes
NCT00590863
Detecting Risk of Suicide in a Pediatric Emergency Department
NCT00623493
PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Frontotemporal Dementia
NCT00613119
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB
NCT00527579
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28
NCT00526916
Antidepressant Effects of NR2B in Major Depression
NCT00472576
Imaging of Cannabinoid Receptors Using New Radioactive Tracer
NCT00450021
PET Whole Body Imaging Using a Peripheral Benzodiazepine Receptor Ligand [C-11]PBR28
NCT00407693
Minocycline to Treat Childhood Regressive Autism
NCT00409747
Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients
NCT00369798
Identifying the Role of Oxytocin and Vasopressin in the Functioning of Neurocognitive Systems Involved in Mood Disorders
NCT00325065
Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia
NCT00128401
The Role of Norepinephrine in Emotional Processing
NCT00109642
Role of Substance P in Post-Traumatic Stress Disorder
NCT00102102
Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F]SPA-RQ
NCT00088738
Rapid Antidepressant Effects of Ketamine in Major Depression
NCT00088699
Lexapro and Pramipexole and to Treat Major Depression
NCT00086307
Family Study of Affective and Anxiety Spectrum Disorders
NCT00071786
Serotonin Transporters in Obsessive-Compulsive-Related Disorders
NCT00082550
Neurocardiac Control in Major Depression
NCT00084162
FMRI Study of Performance During a Probabilistic Reversal Learning Task in Depression
NCT00075296
Evaluating Brain Responses to Facial Expressions in Major Depressive Disorder
NCT00071123
Brain Regulation of Emotions in People With Depression and Anhedonia
NCT00059579
Imaging of Brain Receptors in Healthy Volunteers and in Patients With Schizophrenia
NCT00061789
Brain Imaging in Depression
NCT00050700
Clinical Trial of Memantine for Major Depression
NCT00040261
Ethnic Variations in Antidepressant Response
NCT00047671
Brain Imaging in Alzheimer's Disease
NCT00039702
PET Scanning in Parkinson s Disease
NCT00024622
Effects of Stress Hormones on Emotion and Cognition
NCT00032838
Reward-Related Processes and Brain Function
NCT00029588
Cortical Excitability in Obsessive-Compulsive and Related Disorders
NCT00029068
Clozapine for Treatment-Resistant Mania
NCT00029458
Brain Function in Mentally Ill Adolescents
NCT00025857
Adolescence, Puberty, and Emotion Regulation
NCT00016731
Clinical Trial of Propranolol for Seasonal Affective Disorder
NCT00016666
Use of Transcranial Magnetic Stimulation (TMS) and Magnetic Resonance Imaging (MRI) to Study Visual Attention
NCT00006285
Child & Adolescent Bipolar Disorder Brain Imaging and Treatment Study
NCT00006177
Heart Disease Risk Factors in Major Depression
NCT00001969
Electrophysiology and Blood Flow in Patients With Schizophrenia and Their Siblings
NCT00001921
Neuroimaging of St. John's Wort-Induced Changes of Serotonin Metabolism in Normal Subjects
NCT00001919
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 112 |
| Phase 2 | 11 |
| Phase 3 | 3 |
| Phase 4 | 5 |
Therapeutic Areas
What the Pipeline for National Institute of Mental Health (NIMH) Shows
According to the ClinicalTrials.gov registry, National Institute of Mental Health (NIMH) is linked to 317 US clinical trials across every stage of research activity. Of those, 237 studies are currently recruiting — about 75% of the sponsor's indexed portfolio — and 77 are already marked complete, representing roughly 24% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for National Institute of Mental Health (NIMH) reports 8 late-stage studies (Phase 3 and Phase 4 combined) and 123 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for National Institute of Mental Health (NIMH) is Healthy with 21 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.